Elaine V. Jones
Independent DirectorDr. Elaine V. Jones, Ph.D., was Director of CREATE Medicines, Inc. from March 2021. She serves as Chairman of the Board at Gritstone bio, Inc. since May 2020. She also served as an Independent Director at the company since September 2019. She serves as Chairwoman of Boost Pharma Aps since March 2026 and as Chairwoman of the Board of Directors at Bionyra since 2026. She is a Trustee of HBM Healthcare Investments Ltd since June 2021 and serves as Director at Myeloid Therapeutics Inc since March 2021. Dr. Jones serves as Board Director at Novartis Venture Fund since 2020, Chairwoman of the Board of Directors at Mironid Ltd since 2019 and as an Independent Director at CytomX Therapeutics, Inc. since May 2019. She serves as an Independent Director at NextCure, Inc. since December 2015 and as a Trustee of Juniata College since 2014. She also serves as an Executive Director of Blade Therapeutics, Inc., Autifony Therapeutics Ltd. and Mission Therapeutics Ltd. Dr. Jones is an Observer on the Board of Arrakis Therapeutics, Inc. She was an Independent Director of Ibere Pharmaceuticals from February 2021 until March 2023. At Pfizer Ventures, she served as Vice President, Worldwide Business Development and Senior Partner from December 2008 to April 2019. At Pfizer Venture, she also served as an Executive Director of Venture Capital-Worldwide Business Development from 2008 to April 2019. During her tenure, Dr. Jones was responsible for making and managing venture investments for Pfizer. She served on the Board of Kymera Therapeutics Inc. until April 2019. She served as a Director of Mersana Therapeutics, Inc. from March 2015 to June 2018, Director of Fluidigm Corporation from October 2001 to August 2017 and Director of CytomX Therapeutics, Inc. from December 2014 to December 2016. Dr. Jones also served as a Non-Employee Director of Mirna Therapeutics, Inc. from October 2012 to June 2016, Director of Aquinox Pharmaceuticals Inc. from June 2010 to February 2015 and Director of Flexion Therapeutics, Inc. from September 2009 to June 2014. She was a General Partner of Euclid SR Partners from 2003 to November 2008. She served as a Director of Targacept, Inc. from August 2000 to June 2007. At SR One, she served as Vice President from September 2001 to August 2003 and as Investment Manager from June 1999 to September 2001. At SmithKline Beecham Pharmaceuticals, she served as a Director of Scientific Licensing since 1994 and was a Research Scientist in its Research and Development Division. Her other prior roles include serving as Director at Second Genome, Inc., Nimbus Therapeutics, Inc., NeuroTherapeutics Pharma, Inc., eFFECTOR Therapeutics, Inc., Jnana Therapeutics Inc., InnaPhase Corporation, Acurian, Inc., Nucleonics, Inc. and Avantium Technologies B.V. She also served as a Board Observer at Neuronetics, Inc. and Merus N.V. Dr. Jones holds a B.S. in Biology from Juniata College and a Ph.D. in Microbiology from the University of Pittsburgh. She was a Research Fellow at the Laboratory of Viral Diseases at the National Institute of Allergy and Infectious Diseases (NIAID).
Positions
- Company NameNextCure, Inc.Stock CodeNXTCPositionIndependent DirectorColleagues
- MSMichael S. RichmanCo-Founder, CEO, President & Director
- DSDavid S. KabakoffIndependent Chairman of the Board
- TMTimothy MayerChief Operating Officer
- LCLieping ChenCo-Founder & Chairman of Scientific Advisory Board
- SPSteven P. CobournChief Financial Officer
- KGKevin G. ShawSenior VP & General Counsel
- SWStephen W. WebsterIndependent Director
